What is TIXiMED?
TIXiMED is dedicated to the development and commercialization of TXNIP [tix-nip] inhibiting medication, positioning itself to offer a first-of-its-kind oral therapeutic for both Type 1 and Type 2 Diabetes. This innovative approach targets a critical pathway in diabetes management, aiming to provide a more accessible and effective treatment option for patients worldwide. The company's focus on TXNIP inhibition represents a significant scientific endeavor to address the complex metabolic challenges associated with diabetes.
How much funding has TIXiMED raised?
TIXiMED has raised a total of $2.6M across 1 funding round:
Debt
$2.6M
Debt (2024): $2.7M with participation from Helmsley Charitable Trust
Key Investors in TIXiMED
Helmsley Charitable Trust
Helmsley Charitable Trust is dedicated to increasing access to healthcare, advancing research, and enhancing the quality of life for individuals globally. The trust focuses on various areas including Crohn's disease, rural healthcare, Type 1 diabetes, and supporting vulnerable children in Sub-Saharan Africa. It aims to strengthen health and safety in Israel and invest in underserved populations in New York City. Through its grant programs, the trust funds initiatives that promote better health outcomes and community well-being.
What's next for TIXiMED?
With the recent major strategic investment, TIXiMED is poised for accelerated growth and the scaling of its operations. This enterprise-level funding is expected to fuel critical research and development milestones, potentially advancing the TXNIP inhibiting medication through further clinical trials and towards commercialization. The strategic backing signals strong confidence in TIXiMED's therapeutic approach and its potential to disrupt the diabetes treatment landscape, paving the way for future expansion and market penetration.
See full TIXiMED company page
